The authors reply

New England Journal of Medicine

Volumn 370, Issue 6, 2014, Pages 577-

  Cortes, Jorge E ^a   Talpaz, Moshe ^b   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PONATINIB; PROTEIN KINASE; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

CELL PROLIFERATION; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DOSE RESPONSE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LETTER; MEDICAL RESEARCH; MYELOID LEUKEMIA; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTION; PRIORITY JOURNAL; ACUTE LYMPHOBLASTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; CHRONIC MYELOID LEUKEMIA; FEMALE; MALE; NOTE; THROMBOSIS;

FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDAZINES; THROMBOSIS;

EID: 84893541741     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1315234     Document Type: Letter

References (2)

1. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12.
2. Deininger MW, Shah NP, Cortes JE, et al. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (Pts) with chronic phase chronic myeloid leukemia (CP-CML). Blood 2013;122:652. abstract.